• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Rasagiline – Trima
    / Trima


    Active Ingredient

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Tablets

    30

    partial basket chart 42654

    Dosage

    It may be taken with or without food. The usual dosage is 1mg (1 pill) a day at repetitive times. Rasagiline is not appointed for children and adolescents under 18 years of age.


    Indications

    Treatment of idiopathic Parkinson’s disease (PD) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.


    Contra-Indications

    Hypersensitivity to the active substance or to any of the excipients. Concomitant treatment with other monoamine oxidase (MAO) inhibitors (including medicinal and natural products without prescription e.g. St. John’s Wort) or pethidine.  At least 14 days must elapse between discontinuation of rasagiline and initiation of treatment with MAO inhibitors or pethidine. Rasagiline is contraindicated in patients with severe hepatic impairment.


    Special Precautions

    Please refer to the license holder for further details.


    Side Effects

    Please refer to the license holder for further details.


    Drug interactions

    Please refer to the license holder for further details.


    Pregnancy and Lactation

    Please refer to the license holder for further details.


    Overdose

    Please refer to the license holder for further details.


    Important notes

    Please refer to the license holder for further details.


    Manufacturer
    Trima Israel Pharmaceutical Products Maabarot Ltd. Israel
    CLOSE